WM

Wynn Resorts, Limited Reports Second Quarter 2023 Results

Retrieved on: 
Wednesday, August 9, 2023
Casino, Gaming, Lodging, Entertainment, Destinations, Travel, Encore Boston Harbor, WML, Wynn Las Vegas, Tourism, WM, Interest, WRF, Corporation, WYNN, Wynn Palace, Resort, Amusement park, Video game, Bank, Limited, Wynn Resorts

Wynn Resorts, Limited (NASDAQ: WYNN) ("Wynn Resorts" or the "Company") today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Wynn Resorts, Limited (NASDAQ: WYNN) ("Wynn Resorts" or the "Company") today reported financial results for the second quarter ended June 30, 2023.
  • Net income attributable to Wynn Resorts, Limited was $105.2 million for the second quarter of 2023, compared to net loss attributable to Wynn Resorts, Limited of $130.1 million for the second quarter of 2022.
  • For the second quarter of 2023, operating revenues increased $409.7 million, $243.0 million, $17.0 million, $11.8 million, and $5.5 million at Wynn Palace, Wynn Macau, our Las Vegas Operations, Encore Boston Harbor, and Wynn Interactive, respectively, from the second quarter of 2022.
  • Net income attributable to Wynn Resorts, Limited was $105.2 million for the second quarter of 2023, compared to net loss attributable to Wynn Resorts, Limited of $130.1 million for the second quarter of 2022.

BTG Pactual reports all-time high net income supported by another quarter of record revenues and 22.7% ROAE

Retrieved on: 
Wednesday, August 9, 2023
Central Bank of Brazil, Asset management, Investment banking, Arrell Global Food Innovation Award, SME finance, Banco Pan, Risk management, Retail banking, ERP, Carbon, Financial system, NNM, JV, WM, AUC, Wum, Sales, US, BTG, Acquisition, BTG Pactual, Wealth management, DCM, CADE, Banco, Corporation, Sustainability Bonds, AM, Growth, ESG, ECM, Bank, R, Indra Sistemas, Institutional Investor, Innovation system, Coal, Airline, Creative industries, Security (finance), Renewable energy, Q2, Research

SÃO PAULO, Aug. 9, 2023 /PRNewswire/ -- BTG Pactual (BPAC11) posted another quarter of record revenue and net income. Revenue closed Q2 at R$5.4bn, up 21% y/y, while adjusted net income was R$2.6bn, up 18% y/y. ROAE totaled 22.7%, the highest since 2015. Without the accounting impact of the Banco PAN credit portfolio acquisition, ROAE would have been 25.2%.

Key Points: 
  • Strong net new money of R$61 billion, totaling R$1.4 trillion AuM/WuM
    SÃO PAULO, Aug. 9, 2023 /PRNewswire/ -- BTG Pactual (BPAC11) posted another quarter of record revenue and net income.
  • "We closed the quarter with record revenue and net income in a challenging macroeconomic scenario, demonstrating the resilience and diversification of our business.
  • Net new money of R$61bn proved once again the quality of our franchises and of our network, totaling R$1.4tn in AuM/AuA.
  • BTG Pactual raised R$61bn in Net New Money (NNM), with R$35.4bn in Wealth Management and R$25.4bn in Asset Management.

BTG Pactual reports all-time high net income supported by another quarter of record revenues and 22.7% ROAE

Retrieved on: 
Wednesday, August 9, 2023
Central Bank of Brazil, Asset management, Investment banking, Arrell Global Food Innovation Award, SME finance, Banco Pan, Risk management, Retail banking, ERP, Carbon, Financial system, NNM, JV, WM, AUC, Wum, Sales, US, BTG, Acquisition, BTG Pactual, Wealth management, DCM, CADE, Banco, Corporation, Sustainability Bonds, AM, Growth, ESG, ECM, Bank, R, Indra Sistemas, Institutional Investor, Innovation system, Coal, Airline, Creative industries, Cryptocurrency, Renewable energy, Q2, Research

SÃO PAULO, Aug. 9, 2023 /PRNewswire/ -- BTG Pactual (BPAC11) posted another quarter of record revenue and net income. Revenue closed Q2 at R$5.4bn, up 21% y/y, while adjusted net income was R$2.6bn, up 18% y/y. ROAE totaled 22.7%, the highest since 2015. Without the accounting impact of the Banco PAN credit portfolio acquisition, ROAE would have been 25.2%.

Key Points: 
  • Strong net new money of R$61 billion, totaling R$1.4 trillion AuM/WuM
    SÃO PAULO, Aug. 9, 2023 /PRNewswire/ -- BTG Pactual (BPAC11) posted another quarter of record revenue and net income.
  • "We closed the quarter with record revenue and net income in a challenging macroeconomic scenario, demonstrating the resilience and diversification of our business.
  • Net new money of R$61bn proved once again the quality of our franchises and of our network, totaling R$1.4tn in AuM/AuA.
  • BTG Pactual raised R$61bn in Net New Money (NNM), with R$35.4bn in Wealth Management and R$25.4bn in Asset Management.

WM Announces Second Quarter Earnings

Retrieved on: 
Tuesday, July 25, 2023
Utilities, Construction & Property, Sustainability, Environment, Alternative Energy, Energy, Building Systems, Recycling, Waste management, Conference call, Bank statement, Electricity, British thermal unit, RNG, GAAP, Ratio, WM, EBITDA, Investment, Collection, Natural gas, Depreciation, Transport, Guidance Tamil Nadu, Volume analysis, Conference, Automation, Renewable energy, Fine chemical, Agriculture, Greater Toronto Area

During the second quarter of 2023, $553 million was returned to shareholders, including $283 million of cash dividends and $270 million of share repurchases.

Key Points: 
  • During the second quarter of 2023, $553 million was returned to shareholders, including $283 million of cash dividends and $270 million of share repurchases.
  • In the second quarter, WM opened its Eco Vista renewable natural gas (RNG) facility in Springdale, Ark., the sixth WM-owned RNG facility and the second of the Company’s planned 20 projects in its sustainability growth program.
  • In the second quarter, the Company completed two recycling growth projects, including technology and automation upgrades at its recycling facility in Surprise, Ariz. and the opening of a recycling facility in the Greater Toronto area.
  • ET on July 26, 2023 to discuss the second quarter results.

Dow publishes 2022 INtersections Progress Report, outlining commitments and actions to create long-term value growth and a more sustainable future

Retrieved on: 
Monday, June 19, 2023
LLP, Fluor, Carbon accounting, Intersection, Partnership, Dow, Protocol, ERG, Sustainability Accounting Standards Board, World Economic Forum, WEF, GHG, Dow Jones Sustainability Indices, Recycling, Carbon, Task Force on Climate Related Financial Disclosures, Job satisfaction, TCFD, WM, Aerial Engineering Corporation Standard 6W-3, NYSE, Task force, Student, Steam, Greenhouse gas, GRI, Achievement Medal, Dow Chemical Company, DOW, Nitrogen, CO2, Renewable energy, Cryptocurrency, Deep Decarbonization Pathways Project, Fort Saskatchewan

"Every day we are becoming a stronger, more competitive and future-ready company that is well-positioned to continue delivering value to our customers, employees, shareholders and communities."

Key Points: 
  • "Every day we are becoming a stronger, more competitive and future-ready company that is well-positioned to continue delivering value to our customers, employees, shareholders and communities."
  • Key highlights from the report, which is based on full-year 2022 data, include:
    Advancing Dow's strategy to Decarbonize and Grow, while achieving carbon neutrality by 2050.
  • The 2022 INtersections Progress Report includes disclosures prepared in accordance with the Global Reporting Initiative (GRI) Standards and the Greenhouse Gas (GHG) Protocol.
  • To learn more about Dow's industry-leading contributions toward a better, more sustainable and equitable future, please read our comprehensive 2022 Progress Report here .

Weltmeister International (WM-INTL) : Weltmeister Motor Group (WM) Wenzhou Factory Resumes Operation, the First Batch of Overseas Orders Are Being Dispatched

Retrieved on: 
Monday, June 19, 2023
Automotive Manufacturing, Other Manufacturing, Manufacturing, WM, Kang Yun-seong, Local government, Work, Car, Warehouse

It means backlog of both domestic and foreign orders may be fulfilled and delivered in a short period of time.

Key Points: 
  • It means backlog of both domestic and foreign orders may be fulfilled and delivered in a short period of time.
  • KANG Yun, the person in charge of WM-INTL said, "There has been a gradual progression toward recovery of WM.
  • WM Wenzhou factory's resumption of production shows that after small-scale trial operation, nearly 100 units WM E5 model have been approved and dispatched.
  • The resumption of operations and production of WM Wenzhou factory this time signifies a robust impetus for WM to penetrate the international marketplace.

BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics

Retrieved on: 
Thursday, June 15, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, CLL, Lymphocytosis, Intellectual property, The New England Journal of Medicine, BGNE, Chronic lymphocytic leukemia, SLL, Atrial fibrillation, Cancer, Medicine, Pharmacyclics, PFS, Complaint, WM, SSE, Patient, American Society of Hematology, Mantle cell lymphoma, MCL, Society, ORR, Safety, Pharmaceutical industry, BeiGene

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is aware that Pharmacyclics LLC has filed a complaint against BeiGene, Ltd. and BeiGene USA, Inc., alleging that BeiGene’s BRUKINSA® infringes a Pharmacyclics patent issued on June 13, 2023.

Key Points: 
  • BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is aware that Pharmacyclics LLC has filed a complaint against BeiGene, Ltd. and BeiGene USA, Inc., alleging that BeiGene’s BRUKINSA® infringes a Pharmacyclics patent issued on June 13, 2023.
  • BeiGene’s work is original, and we will vigorously defend against all allegations of patent infringement.
  • BeiGene has developed original and novel intellectual properties around BRUKINSA to demonstrate its differentiated profile.
  • BeiGene also remains committed to making medicines that are more affordable and accessible to cancer patients worldwide.

Cellectar Provides a Research and Development Program Summary

Retrieved on: 
Monday, June 12, 2023
Pancreatic cancer, Maintenance, Society, Neoplasm, Multiple myeloma, Molecular imaging, Survival, NDA, Cancer, Traffic barrier, Q3, CNSL, Phospholipid, WM, Running, Patient, FDA, NCI, Conference, BCMA, Peptide, Fine chemical, Pharmaceutical industry, Medical imaging

FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted treatments for cancer, today provided an update for its iopofosine I 131 clinical program and guidance related to its Waldenstrom’s macroglobulinemia (WM) CLOVER-WaM pivotal trial, as well as preclinical advancements to its proprietary phospholipid ether drug conjugate platform.

Key Points: 
  • Cellectar experienced delays with trial start-up activities, such as site contracting and country regulatory responses, which slowed the initial pace of site initiations resulting in lower-than-expected patient enrollment.
  • The company now has all 49 sites up and running and patient enrollment rates have accelerated.
  • Development of the company’s phospholipid ether cancer targeting platform continues to demonstrate its broad utility to provide targeted intracellular delivery of multiple cancer treatment modalities.
  • James Caruso, president and CEO of Cellectar said, “The company’s priority remains the near-term completion of our WM pivotal study.

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Retrieved on: 
Monday, June 12, 2023
Waldenström macroglobulinemia, University, Chronic lymphocytic leukemia, CRS, Lymphoid leukemia, Fred Hutchinson Cancer Research Center, European Hematology Association, University of Washington, Immunoglobulin M, Bone marrow, BTK, Associate, Translation, WM, CAR, Waldenström, Cytokine release syndrome, Patient, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mustang, DSM-IV codes, Food, Safety, Disease, Pharmaceutical industry

WORCESTER, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”) to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”).

Key Points: 
  • The updated results from the single-institution Phase 1/2 clinical trial were presented during a poster session at the European Hematology Association 2023 Hybrid Congress (“EHA2023”) by Mazyar Shadman, M.D., M.P.H., Associate Professor and physician at Fred Hutch and University of Washington.
  • From a safety perspective, cytokine release syndrome (CRS) occurred in five patients: two patients with grade 1 and three patients with grade 2.
  • No grade 3 or 4 CRS or grade 2, 3 or 4 ICANS has been observed.
  • The MB-106 data from the Phase 1/2 clinical trial taking place at Fred Hutch continue to be encouraging for WM and other B-NHLs.

AM Best Affirms Credit Ratings of National Guaranty Insurance Company of Vermont

Retrieved on: 
Friday, June 9, 2023
Insurance, Professional Services, AM Best, Waste management, ALL, ERM, Perception, Risk management, Credit, WM, AM, NGIC, News, NYSE

AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of National Guaranty Insurance Company of Vermont (NGIC) (Burlington, VT).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of National Guaranty Insurance Company of Vermont (NGIC) (Burlington, VT).
  • For current Best’s Credit Ratings and independent data on the captive and alternative risk transfer insurance market, please visit www.ambest.com/captive .
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .